Alnylam Pharma (ALNY) Announces Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
CEO Departure Likely to Pressure Alnylam (ALNY) Stock, M&A Possibility Will Likely Fade - Analyst
October 28, 2021 8:41 AM EDTEarlier today, alongside its Q3 report, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, at... More
Alnylam Pharma (ALNY) Announces Planned Retirement of CEO John Maraganore
October 28, 2021 7:56 AM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, MBChB, at year-end 2021. Dr. Maraganore joined Alnylam in 2002 as the companys founding CEO and has led the companys advancement of RNAi therapeutics as a whole new class of... More
